Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
676.2
1 302
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd
Long-Term Debt
Zydus Lifesciences Ltd
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Zydus Lifesciences Ltd
NSE:ZYDUSLIFE
|
Long-Term Debt
₹251m
|
CAGR 3-Years
-62%
|
CAGR 5-Years
-63%
|
CAGR 10-Years
-32%
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Long-Term Debt
₹7.4B
|
CAGR 3-Years
7%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Long-Term Debt
₹2.2B
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-41%
|
CAGR 10-Years
-3%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Long-Term Debt
₹3.7B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
5%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Long-Term Debt
₹14.7B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-4%
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Long-Term Debt
₹325.8m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Zydus Lifesciences Ltd
Glance View
Zydus Lifesciences Ltd., a resilient player in India's pharmaceutical industry, traces its origins back to 1952, when it was founded in Ahmedabad. Over the decades, it has metamorphosed from a modest venture into a global healthcare presence, with a diverse repertoire that spans across pharmaceuticals, animal health, and consumer wellness products. The company's ethos is deeply embedded in innovation, steadfastly pursuing research and development to propel its pipeline of generics, novel therapeutics, and vaccines. With a robust manufacturing infrastructure spread across continents, Zydus ensures seamless distribution and availability of its products, thereby maintaining a key foothold in both established and emerging markets. The lifeblood of Zydus's profitability streams from its comprehensive product portfolio, catering to a myriad of therapeutic areas such as cardiology, gastroenterology, and women's health, among others. It generates revenue primarily through the sale of branded generics and active pharmaceutical ingredients (APIs). Strategic alliances and collaborations further bolster its growth trajectory, providing new avenues for market expansion and technological advancements. As the firm continues to navigate the complex landscape of global healthcare demands, it remains anchored to its core mission of delivering accessible and affordable healthcare solutions, ensuring that it not only sustains its economic pulse but also positively impacts countless lives worldwide.
See Also
What is Zydus Lifesciences Ltd's Long-Term Debt?
Long-Term Debt
251m
INR
Based on the financial report for Sep 30, 2024, Zydus Lifesciences Ltd's Long-Term Debt amounts to 251m INR.
What is Zydus Lifesciences Ltd's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
-32%
Over the last year, the Long-Term Debt growth was -18%. The average annual Long-Term Debt growth rates for Zydus Lifesciences Ltd have been -62% over the past three years , -63% over the past five years , and -32% over the past ten years .
You don't have any saved screeners yet
